Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer

Cancer Gene Therapy volume 16, pages 841–847 (2009)Cite this article

Abstract

Pancreatic adenocarcinoma is an aggressive and highly lethal malignancy. Currently, gemcitabine is commonly used in patients with pancreatic cancer. However, the life expectancy of pancreatic cancer patients remains poor. We explored the possibility of increased anti-tumor activity by combining human tumor necrosis factor-alpha (hTNF-α) with current front-line therapy. Human TNF-α displays potent anti-tumor activity, but its use is limited by the toxicity of systemic administration. We developed a gene delivery approach using intratumoral injections of an adenoviral vector expressing hTNF-α, AdEgr.TNF.11D (TNFerade), to increase local concentrations of hTNF-α within the tumor, thereby maximizing local anti-tumor activity and yet minimizing the systemic toxicities. An ongoing phase III clinical trial is testing the efficacy of AdEgr.TNF.11D-injected intratumorally and combining with chemotherapy in locally advanced pancreatic cancer. In this study, we show that treatment with AdEgr.TNF.11D and gemcitabine results in a high level of hTNF-α expression in human pancreatic cancer cell lines. The combined treatment was well tolerated, highly active and produced marked delays in the growth of human pancreatic xenograft tumors relative to either agent alone. Our results strongly suggest that combination of AdEgr.TNF.11D and gemcitabine may be a potentially useful therapeutic approach for the improved treatment of pancreatic cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 2
Figure 1
Figure 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ . Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.

    Article  Google Scholar 

  2. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413.

    Article  CAS  Google Scholar 

  3. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R . Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006; 5: 1387–1395.

    Article  CAS  Google Scholar 

  4. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007; 1773: 1095–1106.

    Article  CAS  Google Scholar 

  5. Mocellin S, Rossi CR, Pilati P, Nitti D . Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005; 16: 35–53.

    Article  CAS  Google Scholar 

  6. MacGill RS, Davis TA, Macko J, Mauceri HJ, Weichselbaum RR, King CR . Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis 2007; 24: 521–531.

    Article  CAS  Google Scholar 

  7. Mauceri HJ, Beckett MA, Liang H, Sutton HG, Pitroda S, Galka E et al. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther 2009; 16: 373–381.

    Article  CAS  Google Scholar 

  8. Lejeune FJ, Lienard D, Matter M, Ruegg C . Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006; 6: 6.

    PubMed  Google Scholar 

  9. Marr RA, Hitt M, Muller WJ, Gauldie J, Graham FL . Tumour therapy in mice using adenovirus vectors expressing human TNFa. Int J Oncol 1998; 12: 509–515.

    CAS  PubMed  Google Scholar 

  10. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR et al. TNFerade biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002; 9: 951–957.

    Article  CAS  Google Scholar 

  11. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004; 22: 592–601.

    Article  CAS  Google Scholar 

  12. Posner M, Chang KJ, Rosemurgy A, Stephenson J, Khan M, Reid T et al. Multi-center, phase 2/3, randomized, controlled clinical trial using TNFerade gene delivery combined with chemoradiation in patients with locally advanced pancreatic cancer (LPAC). Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2007.

  13. Lopez CA, Kimchi ET, Mauceri HJ, Park JO, Mehta N, Murphy KT et al. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 2004; 3: 1167–1175.

    Article  CAS  Google Scholar 

  14. Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE et al. Transcriptional control of viral gene therapy by cisplatin. J Clin Invest 2002; 110: 403–410.

    Article  CAS  Google Scholar 

  15. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I . A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996; 70: 6497–6501.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Kazuno H, Sakamoto K, Fujioka A, Fukushima M, Matsuda A, Sasaki T . Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine(ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line. Cancer Sci 2005; 96: 295–302.

    Article  CAS  Google Scholar 

  17. Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T . Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 1998; 9: 1409–1417.

    Article  CAS  Google Scholar 

  18. Gupta VK, Park JO, Jaskowiak NT, Mauceri HJ, Seetharam S, Weichselbaum RR et al. Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol 2002; 9: 500–504.

    Article  Google Scholar 

  19. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786–791.

    Article  CAS  Google Scholar 

  20. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR . Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998; 5: 293–300.

    Article  CAS  Google Scholar 

  21. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W . Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992; 10: 406–413.

    Article  CAS  Google Scholar 

  22. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491–498.

    Article  CAS  Google Scholar 

  23. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W . Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27: 258–262.

    Article  CAS  Google Scholar 

  24. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80: 751–755.

  25. Pober JS, Min W . Endothelial cell dysfunction, injury and death. Handb Exp Pharmacol 2006; 176 (Pt 2): 135–156.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge the expertise of Ms. Leslie West-Bushby in providing assistance with animal procedures for in vivo studies. Also, we thank Ms. Melissa Hamilton for her assistance in manuscript preparation.

Author information

Authors and Affiliations

  1. Department of Research, GenVec Inc, Gaithersburg, MD, USA

    S R Murugesan, C R King, R Osborn, M O Thornton & L L Wei

  2. Flower Valley Consulting Inc, Rockville, MD, USA

    W R Fairweather

  3. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    E M O'Reilly

Authors
  1. S R Murugesan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C R King
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Osborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W R Fairweather
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E M O'Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M O Thornton
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L L Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L L Wei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murugesan, S., King, C., Osborn, R. et al. Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther 16, 841–847 (2009). https://doi.org/10.1038/cgt.2009.32

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2009.32

Keywords

This article is cited by

Search

Advanced search

Quick links